Fezolinetant for hot flashes in women with breast cancer on hormone therapy
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called fezolinetant to see if it reduces hot flashes in women with HR+ breast cancer who are on hormone therapy (like tamoxifen or aromatase inhibitors). You need to be postmenopausal and having at least 7 moderate to severe hot flashes a day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman with stage I-III HR+ breast cancer and on hormone therapy for at least 3 months.
- You must be postmenopausal (no periods for 12 months, or have had your ovaries removed, or be on medication to suppress ovaries).
- You must have at least 7 moderate to severe hot flashes per day for a week.
- You cannot have cancer that has spread to other parts of the body (stage IV).
- You cannot be taking certain medications for hot flashes or other cancer treatments (like chemo or immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
This study looks at how hot flashes in midlife women might be connected to heart disease risk. Researchers want to see if managing hot flashes can improve heart health.
This trial tests a new medication called fezolinetant to reduce hot flashes (sudden feelings of intense heat) in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of this treatment, and this study aims to see if fezolinetant can help relieve them.
This study tests whether fezolinetant, a new medication, can reduce moderate-to-severe hot flashes and night sweats during menopause while protecting heart and brain health. Participants will receive the study drug or placebo and have regular check-ups including brain imaging.
This trial tests a non-hormonal pill called fezolinetant to reduce hot flashes in men with prostate cancer who are on hormone therapy. If you have daily, bothersome hot flashes, this study may help you find relief.
This study follows women in Canada who are starting fezolinetant, a new medication for hot flashes during menopause. Researchers will track how well it works and how you feel while using it in your regular doctor's care.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.